Latest news with #GerresheimerAG
Yahoo
28-05-2025
- Business
- Yahoo
What Does Gerresheimer AG's (ETR:GXI) Share Price Indicate?
While Gerresheimer AG (ETR:GXI) might not have the largest market cap around , it led the XTRA gainers with a relatively large price hike in the past couple of weeks. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. But what if there is still an opportunity to buy? Today we will analyse the most recent data on Gerresheimer's outlook and valuation to see if the opportunity still exists. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. According to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 26.77x is currently trading slightly below its industry peers' ratio of 32.29x, which means if you buy Gerresheimer today, you'd be paying a reasonable price for it. And if you believe that Gerresheimer should be trading at this level in the long run, then there's not much of an upside to gain over and above other industry peers. Furthermore, it seems like Gerresheimer's share price is quite stable, which means there may be less chances to buy low in the future now that it's priced similarly to industry peers. This is because the stock is less volatile than the wider market given its low beta. See our latest analysis for Gerresheimer Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to more than double over the next couple of years, the future seems bright for Gerresheimer. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. Are you a shareholder? It seems like the market has already priced in GXI's positive outlook, with shares trading around industry price multiples. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at GXI? Will you have enough conviction to buy should the price fluctuate below the industry PE ratio? Are you a potential investor? If you've been keeping tabs on GXI, now may not be the most advantageous time to buy, given it is trading around industry price multiples. However, the optimistic forecast is encouraging for GXI, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. To help with this, we've discovered 4 warning signs (2 are potentially serious!) that you ought to be aware of before buying any shares in Gerresheimer. If you are no longer interested in Gerresheimer, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Bloomberg
12-03-2025
- Business
- Bloomberg
Warburg Pincus, KKR in Advanced Talks to Buy Gerresheimer
A consortium consisting of Warburg Pincus and KKR & Co. are in talks to acquire Gerresheimer AG, the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. Shares of Gerresheimer have risen about 12% this year, giving the company a market value of about €2.74 billion ($3 billion).
